| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 7.63 | 9.99 | 20.31 | 5.21 |
Op profit growth | 0.42 | 39.79 | 6.98 | 14.19 |
EBIT growth | -6.24 | 42.86 | 5.2 | 11.09 |
Net profit growth | -2.35 | 61 | 5.44 | 22.92 |
Profitability ratios (%) | ||||
OPM | 21.78 | 23.34 | 18.36 | 20.65 |
EBIT margin | 16.66 | 19.13 | 14.73 | 16.84 |
Net profit margin | 11.61 | 12.8 | 8.74 | 9.98 |
RoCE | 12.51 | 17.21 | 15.87 | 18.51 |
RoNW | 4.03 | 5.88 | 5.66 | 6.31 |
RoA | 2.18 | 2.88 | 2.35 | 2.74 |
Per share ratios (₹) | ||||
EPS | 30.72 | 31.38 | 42.57 | 39.89 |
Dividend per share | 3 | 3.5 | 1 | 1 |
Cash EPS | 16.76 | 20.13 | 22.96 | 23.53 |
Book value per share | 201.04 | 170.96 | 194.14 | 165.91 |
Valuation ratios | ||||
P/E | 18.7 | 10.59 | 5.61 | 4.01 |
P/CEPS | 34.26 | 16.5 | 10.41 | 6.79 |
P/B | 2.85 | 1.94 | 1.23 | 0.96 |
EV/EBIDTA | 25.84 | 15.33 | 16.06 | 11.93 |
Payout (%) | ||||
Dividend payout | 4.99 | 8.12 | 2.44 | 2.6 |
Tax payout | -19.46 | -19.13 | -19.31 | -21.18 |
Liquidity ratios | ||||
Debtor days | 62.66 | 61.38 | 56.55 | 60.46 |
Inventory days | 71.74 | 69 | 63.23 | 61.53 |
Creditor days | -47.71 | -39.96 | -38.6 | -43.98 |
Leverage ratios | ||||
Interest coverage | -8.69 | -6.41 | -4.25 | -4.54 |
Net debt / equity | 0.69 | 0.62 | 1.29 | 1.12 |
Net debt / op. profit | 2.49 | 1.89 | 2.93 | 2.34 |
Cost breakup (₹) | ||||
Material costs | -47.23 | -49.12 | -57.31 | -55.1 |
Employee costs | -8.24 | -7.29 | -4.99 | -4.81 |
Other costs | -22.73 | -20.24 | -19.31 | -19.42 |
The company said the contracts have been signed with overseas manufacturers and suppliers located across the GCC region and parts of South East Asia
Pharma's volume increased significantly during the pandemic and has now stabilised since FY24.
Here are some of the stocks that may see significant price movement today: Tata Motors, Asian Paints, Divi’s Laboratories, etc.
Here are some of the stocks that may see significant price movement today: Mazagon Dock Shipbuilders, Krsnaa Diagnostics, Dr Reddy's, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
